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AbstrAct:
NSP 5a3a along with three other distinct though similar splice variants were initially 
identified corresponding to locus HCMOGT-1 on chromosome 17p11.2 [1].  Secondary 
structure analysis of the novel structural protein (NSP) isoforms revealed similarity 
to Spectrin like proteins containing coiled coil domains [1].  The NSP 5a3a isoform had 
been found to be highly expressed in-vitro in particular cancer cell lines while very 
low to un-detectable levels in normal body tissues [1].  Subsequent investigation of 
this isoform revealed its novel interaction with B23 [2], a multifunctional nucleolar 
protein involved in ribosome biogenesis, rRNA transcription, mitosis, cell growth 
control,  and  apoptosis  [3].    Subsequent  investigation,  elucidated  NSP  5a3a’s 
potential involvement in cellular processes such as ribosome biogenesis and rRNA 
processing  by  validating  NSP  5a3a’s  novel  interaction  with  B23  and  ribonuclear 
protein hnRNP-L possibly implicating NSP 5a3a’s involvement in cellular activities 
such as RNA metabolism and processing [4].  In this preliminary investigation, we 
wanted to observe the effect that over-expressing NSP 5a3a may have on cell cycle 
and its potential application in cancer treatment in aggressive cancers such as head 
and neck carcinomas.  Over-expressed NSP 5a3a in HN30 cells induced a significant 
degree of apoptosis, an average of a 10.85 fold increase compared to controls 3 
days post-transfection. This effect was more significant then the apoptosis observed 
between Fadu cells over-expressing NSP 5a3a and its controls. Though, the apoptosis 
induced in the WI38 control cell line showed an average of a 13.2 fold increase between 
treated  and  controls  comparable  to  the  HN30  cell  line  3  days  post-transfection.   
Molecular  analysis  indentified  a  novel  p73  dependent  mechanism  independent 
of p53 and caspase 3 activity through which NSP 5a3a is inducing apoptosis.  
We propose NSP 5a3a as a potential therapeutic target for site directed cancer 
treatment in perhaps certain head and neck carcinomas by induction of apoptosis.
IntroductIon
Generally, the process of apoptosis is a critical and 
essential cellular function allowing regulated turn-over 
of cells during embryonic development, differentiation, 
and in response to disease [5-6].  Typically, this 
complex process which regulates cellular homeostasis is 
characterized by distinct morphological and biochemical 
signatures including nuclear condensation, cell shrinkage, 
formation of apoptotic bodies, cellular blebbing and the 
externalization of phosphatidylserine [5-6].  Apoptosis 
can be described as a series of tightly regulated series 
of molecular events that occur over three distinct stages 
though involve multiple and in tandem molecular 
pathways of activation [7].  Initially, there is a signaling 
stage, which results from various apoptotic stimuli such as 
DNA damage, growth factors, death receptor activation, 
and cytokines [7]. Each of these stimuli can respectively 
activate a subsequent initiator of apoptosis or inhibitor of 
anti-apoptosis, such as PUMA/Noxa, Bad, Bid, and Bim 
[7-8].  PUMA and/NOXA as well as Bad can inhibit anti-
apoptotic members Bcl-2/Bcl-Xl members where Bid Oncotarget 2010; 1:  423 - 435 424 www.impactjournals.com/oncotarget
and Bim can activate pro-apoptotic members Bax/Bak [7-
8].  This activation of Bax and Bak leads to the cellular 
commitment stage in apoptosis by which there is an 
organelle dysfunction of the mitochondria and endoplasmic 
reticulum characterized along with a change in organelle 
homeostasis involving calcium levels in turn promoting 
the release of apoptogenic factors from mitochondria 
[7-8].  The release of apoptogenic factors such as: of 
Cytochrome C, SMAC/Diablo, Omi/HtrA2, and AIF 
(Apoptosis inducing factor) in turn mark the execution 
stage in which activate further downstream pathways 
leading to the common end result of cell death [7-8].   
Cytochrome C will form a molecular complex with Apaf-
1 and caspase 9 leading to formation of an Apoptosome 
that in turn can activate down-stream effectors such as 
caspase 3, 6, and 7 [7-8].  SMAC/Diablo along with Omi/
HtrA2 can bind to IAPs (inhibitors of apoptosis proteins), 
such as XIAP and cIAP1, disabling them from inhibiting 
caspase activation.  AIF and endonuclease G can lead to 
DNA degradation and in turn to cell death independent of 
caspase activation pathways [7-8].
Mediators of apoptosis and cell cycle arrest such as 
p53 and its family members p63 and p73 which exhibit 
p53-like activities which can transactivate many p53 
target genes such as PUMA, NOXA, BAX, p21, GAdd45,   
and MDM2 which are involved as well in apoptosis and 
cell cycle arrest [9-10].  Typically, when there is DNA 
damage, hypoxia, and certain oncogenic insult, p53 
becomes activated and stabilized by post-translational 
modifications which in turn can activate the execution of 
the intrinsic apoptotic pathway through transactivation of 
pro-apoptotic genes such as BAX, PUMA, NOXA, BIG 
and Apaf-1, as well as others [11].  
Head and Neck squamous cell carcinomas 
(HNSSCs) usually are responsible for nearly 90% of 
all cancers originating from head and neck regions [12] 
such as lip/boccal cavity and various regions associated 
with the pharynx and larynx [13] making them quite 
clinically, biologically, and pathologically unique and 
diverse [14].  It’s the eighth most common cancer 
in United States with approximately 40,000 to some 
47,000 new cases diagnosed each year [12, 14] and 
despite on-going available treatments and combinations 
involving surgery, chemotherapy, and radiotherapy the 
prognosis and survival rate of patients with head and 
neck cell carcinomas is still poor and has not improved 
significantly [12].  Thus, there has been an urgency to 
detect potential novel tumor markers for HNSCCs as well 
as develop new drugs and therapies.  Recently, there has 
been growing evidence suggesting the use of biological 
therapies or molecular based therapies that target cancer 
cells possibly increasing these cells sensitivity to radio 
and chemotherapy treatments involving lower doses or 
exposures with minimal cytotoxic effects to surrounding 
healthy cells [15].  
NSP 5a3a along with the other three isoforms, NSP 
5b3a,  5a3b,  and  5b3b  were  identified  having  marginal 
homology to SMC (structural maintenance chromosome), 
SMC like proteins, DNA repair Sbc proteins, and high 
similarity to Specc1 and Cytospin A renal carcinoma 
antigen whose functions are functions are still unknown.   
The NSP isoforms contain four coiled coil regions 
characteristic of Spectrin like proteins [2].  These NSP 
isoforms having features of Spectrin like repeat proteins 
suggests they may well be part of this protein superfamily 
as novel members. Generally, Spectrin and Spectrin like 
proteins have important roles in intracellular structural 
integrity relating to the cytoskeleton and matrix in both 
the cytoplasm and nucleus [16-17].   Furthermore, proteins 
in this superfamily have been found to be involved in 
intracellular  trafficking  in  secretory  pathways  [18], 
maintenance of organelle function, integrity [18], and 
endocytosis [19], nuclear reassembly in Telophase [20], 
serving as scaffolding proteins with actin and membrane 
bound proteins in intracellular signaling pathways [21].
The NSP 5a3a isoform was found to be have 
differential expression in several cancer cell lines in-vitro 
though quite high in HT-29, MCF-7, Hela, HN30, Saos-2, 
CEM, and H23 [2]. NSP 5a3a and NSP 5a3b were shown 
to interact with a multi-functional nucleophos-phoprotein 
known as B23 (Numatrin or Nucleophosmin) in Hela cells 
particularly in mitotic Hela cells.  This implied a possible 
involvement of these two isoforms in mitosis in relation 
to B23 and possibly other B23 functions too [2].   A 
subsequent study demonstrated that NSP 5a3a, B23, and 
hnRNP-L (heterogeneous ribonuclearprotein) interacted 
with each other in both MCF-7 (breast adenocarcinoma) 
and MCF-12A (normal breast) cell lines though in a both 
site-specific  and  cell  specific  manner  [4].    This  novel 
interaction between NSP 5a3a with B23 and hnRNP-L 
raised possibilities of NSP 5a3a being involved in RNA 
metabolism and RNA processing both of which B23 and 
hnRNP-L are involved [4].
Through over-expression of NSP 5a3a in HN30, 
Fadu,  and  WI38  we  observed  a  significant  level  of 
apoptosis 3 days post-transfection in HN30 cells (7 to 
16.42 fold increase compared to controls) and WI38 
cells (11 to 13.45 fold increase compared to c ontrols), 
both being p53 functional [28-29] though through a p53 
independent pathway.  In contrast, levels of apoptosis 
were comparable in the Fadu cell line (1.07 to 1.13 fold 
decrease) being p53 mutant non-functional [30].  We 
propose NSP 5a3a as a potential therapeutic target to 
consider in site-directed delivery to treat cancer in perhaps 
certain head and neck carcinomas with a similar novel p73 
dependent mechanism as the one identified in this study.
results
Morphological and FAcs analysis of Fadu over-
expressing nsP 5a3aOncotarget 2010; 1:  423 - 435 425 www.impactjournals.com/oncotarget
Asynchronous Fadu cells were transfected with 
pcDNA3.0 NSP 5a3a vector along with controls after 
which images of the cells were taken three days post-
transfection and prepared for FACS analysis to assess 
the effect of NSP 5a3a over-expression on cell cycle.   
Images of Fadu cells three days post-transfection revealed 
that treated cells with NSP 5a3a seemed comparable to 
the controls (Fig. 1.)  Controls and treated cells were 
seemingly  still  confluent  and  with  well  attached  cell 
populations (Fig. 1.).  FACS analysis revealed that there 
was no significant difference observed between treated 
cells and controls as well as no significant shifts in cell 
cycle in treated cells as compared to the controls (Fig. 4.). 
Morphological and FAcs analysis of Hn30 over-
expressing nsP 5a3a
Asynchronous HN30 cells were transfected with 
pcDNA3.0 NSP 5a3a vector along with controls after 
which images of the cells were taken three days post-
transfection and prepared for FACS analysis to assess the 
effect of NSP 5a3a over-expression on cell cycle.  Images 
of HN30 cells three days post-transfection revealed that 
treated cells with NSP 5a3a seemed highly apoptotic 
compared to the controls (Fig. 2.)  Controls were seemingly 
still confluent and well attached cell populations while 
the treated cells with NSP 5a3a showed a high degree 
of detached cells in media with very few cells attached 
(Fig.2).  The initial verification of possible apoptosis was 
verified by FACS analysis which demonstrated that the 
treated cells over-expressing NSP 5a3a had an average 
of a10.85 fold increase in apoptosis compared to controls 
(Fig. 5.).  Consequently, there was a 5 fold decrease in 
treated cells found in G1/G0 while no significant change 
in the G2/M and S phases was observed in the treated cells 
as compared to the controls (Fig. 5).
Morphological and FAcs analysis of WI38 over-
expressing nsP 5a3a
Asynchronous WI38 cells were transfected with 
pcDNA3.0 NSP 5a3a vector along with controls after 
which images of the cells were taken three days post-
transfection and prepared for FACS analysis to assess the 
effect of NSP 5a3a over-expression on cell cycle.  Images 
of WI38 cells three days post-transfection revealed that 
treated cells with NSP 5a3a seemed highly apoptotic 
compared to the controls (Fig. 3.) similar to what was 
observed in the HN30 cell line.  Controls were seemingly 
still confluent and well attached cell populations while 
the treated cells with NSP 5a3a showed a high degree 
of detached cells in media with very few cells attached 
(Fig.3).  Verification of possible apoptosis was confirmed 
by FACS analysis which demonstrated that the treated 
cells over-expressing NSP 5a3a had an average of 13 
fold increase in apoptosis compared to controls (Fig. 6.).   
There was approximately an average of a 2 fold decrease 
in both Go/G1 and G2/M phases in treated as compared 
to controls though no significant changes observed in S 
phase (Fig. 6).
Molecular analysis of nsP 5a3a over-expression 
in Fadu
Western blot analysis of total lysates of Fadu cells 
from three days post-transfection along with controls were 
analyzed to understand the possible mechanism involved 
Figure 1:  Morphological observation of Fadu cells 3 days 
post-transfection.  NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.
Figure 2:  Morphological observation of Hn30 cells 3 days 
post-transfection.  NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.Oncotarget 2010; 1:  423 - 435 426 www.impactjournals.com/oncotarget
in the absence of  an appreciable apoptotic response when 
over-expressing NSP 5a3a in this particular p53 mutant 
cell line [30].  There was no apparent significant change in 
P53, B23, Bax, nucleolin, and Cytochrome c protein levels 
between treated and the controls. Procaspase 3 levels as 
well were comparable between controls and treated cells 
though no cleaved caspase 3 products of 17 and 19 Kda 
were detected in treated nor in controls.  There was no 
apparent change in un-cleaved Parp 116Kda between 
treated and controls as also no cleaved Parp product of 
89 Kda and 24 Kda was detected either in all conditions.   
Un-cleaved MDM2 around 90 Kda was not detected in all 
conditions though there seemed to a substantial increase 
in the cleaved MDM2 product 60 Kda in the treated cells 
as compared to the controls.  A possible high molecular 
weight P73 isoform around 140 Kda or above were 
detected in both treated and controls though treated cells 
showed a moderate increase in that particular p73 isoform 
(Fig. 7.).  Though, no other p73 isoforms around the 73 
Kda range were detected for all conditions.  Arf and p21 
levels were not detected in both treated and controls (data 
not shown).
Molecular analysis of nsP 5a3a over-expression 
in Hn30
Western blot analysis of total lysates of HN30 cells 
from three days post-transfection along with controls 
were analyzed to elucidate the possible pathway that NSP 
5a3a may be affecting in order to induce apoptosis in this 
particular p53 functional cell line [28].  Proteins involved 
in apoptosis (p53 dependent and independent manner) as 
well as known to interact with B23 were considered to 
be studied given the established interaction between NSP 
5a3a and B23 in Hela [2] as also in MCF-7 and MCF-
12A cells [4].  Bax levels while apparently very low in 
the cell line showed possibly a slight decrease between 
treated and controls cells.  P53 levels also being very 
low in all conditions appeared to have possibly a slight 
decrease in treated cells as compared to the controls.  B23 
levels showed a slight apparent increase in expression 
in the treated compared to the controls.  Procaspase 3 
levels were comparable between controls and treated cells 
though no cleaved caspase 3 products of 17 and 19 Kda 
were detected in treated nor in controls.  A cleaved Parp 
product around 89 Kda was detected in treated cells but 
not in the controls while no un-cleaved Parp around 116 
Kda and smaller Parp product of 24 Kda was detected in 
the treated and controls.  Low levels of un-cleaved MDM2 
around 90Kda and possibly cleaved around 60Kda were 
detected in controls though an apparent decrease of both 
un-cleaved and cleaved were observed in the treated cells.   
Nucleolin levels while apparently low in the cells line 
seemed to be decreased in the treated when compared to 
the controls. Possible high molecular weight P73 isoforms 
around 140 Kda and above were detected in both treated 
and  controls  though  treated  cells  showed  a  significant 
decrease in that particular p73 isoform.  No p73 isoforms 
around the 73 Kda range were detected for all conditions.   
Finally, Cytochrome c levels were comparable between 
controls and treated (Fig. 8.). Arf and p21 levels were not 
detected in both treated and controls (data not shown).
Molecular analysis of nsP 5a3a over-expression 
in WI38
Western blot analysis of total lysates of WI38 cells 
from three days post-transfection along with controls were 
Figure 3:  Morphological observation of WI38 cells 3 days 
post-transfection.  NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.
Figure 4: FAcs analysis of asynchronous Fadu cells 3 days 
post-transfection. NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.Oncotarget 2010; 1:  423 - 435 427 www.impactjournals.com/oncotarget
analyzed to elucidate the possible pathway that NSP 5a3a 
may be affecting in order to induce apoptosis again in this 
particular p53 functional cell line [29]. 
There was no apparent significant change in p53, B23, 
Bax (low levels), Nulceolin (low levels), and Cytochrome 
c protein levels between treated and controls.  P73 protein 
levels showed a moderate decrease in treated compared 
to controls again only high molecular weight p73 isoform 
around or above 140 Kda was detected in all conditions.   
Procaspase 3 levels were comparable between treated and 
controls and no cleaved caspase product was detected. 
Un-cleaved Parp levels were also comparable between 
treated and controls while no cleaved Parp products were 
detected in treated and controls.  Interestingly, only an 
apparent decrease in both un-cleaved and cleaved MDM2 
while low was observed in treated cells as compared to 
controls. Arf and p21 levels were not detected in both 
treated and controls (data not shown).
dIscussIon
Apoptosis is critical to maintenance of homeostasis 
in normal cells also having an important role in 
tumorigenesis [25-26].  It has been characterized in by 
specific  cellular,  biochemical,  and  molecular  events 
during normal cell turnover, cellular differentiation,
organogenesis, and embryonic development as well 
[27-28].  Typically, apoptosis also known as programmed 
cell death can be initiated through two main separate 
pathways that ultimately converge downstream resulting 
in cell death through the mitochondria: the extrinsic and 
intrinsic pathway [28].
The extrinsic pathway is usually initiated by external 
stimuli such as cytokines like TNF, TRAL, and CD95/
Fas/Apo-1 families, who bind to specific membrane death 
receptors, which in turn through an adaptor protein such 
as Fas which has a death domain, can bind to Procaspase 
8 or 10 [8, 29]. This in turn, activates the caspase 
promoting its cleavage with the subsequent activation/
cleavage of caspases 3 and 7.  Activation of caspase 3 
by caspase 8 can occur by 2 pathways [30].  Caspase 8 
activation occurs through self-cleavage and activation 
which can activate and cleave pro-apoptotic proteins 
such as BID.  This results in cytochrome c release as well 
as other pro-apoptotic proteins, AIF and Endo G which 
lead to DNA fragmentation, and antagonists of  (IAPs) 
inhibitors of apoptosis, Smac/Diablo and HtrA2/Omi [8].   
The release of cytochrome c also and binding to dATP 
leads to formation of an apoptosome with Apaf-1 and 
procaspase 9 which in turns results in caspase 9 activation 
and subsequent activation of caspase 3.  Another manner 
of caspase 3 activation is by direct activation of caspase 
3 by caspase 8 [30].  Finally, caspase 3 activation leads to 
cleavage of death substrates and cell death.
The intrinsic pathway is usually triggered in 
response to internal insults such as from oxidative stress, 
direct DNA damage, oncogenes, hypoxia, and depletion 
of survival factors [31-32].   Activation of the intrinsic 
pathway usually occurs through the stabilization and 
activation of p53, a well known regulator of cell growth 
arrest and apoptosis [31-32].  This activation leads to 
transcriptional activation of pro-apoptotic proteins such 
as Bax and BID as well as modulators of apoptosis, Puma/
Noxa [31]. Bax, BID, and BIM can either be involved 
in formation of pore formation in the mitochondrial 
membrane leading to release of cytochrome c and other 
apoptogenic factors as in the extrinsic pathway and also 
be involved in antagonizing anti-apoptotic proteins, BCl-
Figure 5:  FAcs analysis of asynchronous Hn30 cells 3 
days post-transfection. NT: non-treated, OB: only buffer, EGFP: 
only pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-
GFP and pcDNA 3.0 NSP 5a3a.
Figure 6:  FAcs analysis of asynchronous WI38 cells 3 days 
post-transfection. NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.Oncotarget 2010; 1:  423 - 435 428 www.impactjournals.com/oncotarget
2 BCL-XL, and BFL1 [31].  Subsequent activation of 
caspase 9 and down-stream effectors such as caspase 3 
and 7 lead to the same cell fate as in the extrinsic pathway.
The investigation of novel molecular targets for use 
in treatment not only in head and neck carcinomas but 
other aggressive cancers with typically poor prognosis 
is crucial regardless of the emergence of new cytotoxic 
drugs whose toxicity is still high with overall low survival 
expectancy [15].
This preliminary study demonstrated that over-
expression of NSP 5a3a induced a significant degree of 
apoptosis in both HN30 and the control cell line WI38 
both being p53 functional [22-23] though through a 
slightly different mechanism in-vitro.  The NSP 5a3a 
isoform seems to be involving two possible nodes of 
interaction in its induction of apoptosis in the case of 
HN30 and one for both Fadu and WI38.  The node being 
altered, unique to the HN30 cell line (Fig. 8), is the one 
involving Nucleolin and Parp, which remained unchanged 
in the Fadu and WI38 cell lines (Fig. 7 and 9).  The other 
node of interaction shared among all three cell lines is the 
one involving MDM2 and p73, one that seemingly is up-
regulated in the Fadu cell line (Fig. 7) and down-regulated 
in the HN30 and WI38 cell lines (Fig. 8 and 9).
Though before interpreting the possible mechanisms 
of action thru which NSP 5a3a is inducing apoptosis in 
these cell lines let us indicate the commonalities between 
all three cell lines.  In all three cell lines (Fig. 7, 8, 9), 
there was no significant changes observed between the 
controls and treated cells for the following proteins which 
can be involved in apoptosis: p53 levels [31], B23 [33], 
Bax [34], cytochrome c [35], as well as p14Arf [36] and 
p21 [37] even though not shown.  This indicated to us 
that the mechanisms of apoptosis were independent of 
these proteins as well as of caspase 3 since there was the 
absence of caspase 3 activation [38].
HN30 cells clearly showed the presence of a cleaved 
Parp product of 89 Kda though its levels were low along 
with the down-regulation of nucleolin (Fig. 8).  Cleavage 
of Parp usually can be usually accomplished by all caspases 
in-vitro while only caspase 3 and 7 in-vivo known to be 
a classical sign of apoptosis in the cells [39].  While no 
caspase 3 activation was detected for HN30 cells (Fig. 8) 
pointing to  a caspase 3 independent proteolysis of Parp 
one cannot exclude the possibility of other caspases such 
as caspase 9 to be involved that can also initiate apoptosis 
independently of caspase 3 [40].  
Parp cleavage has been associated with apoptosis 
independent of caspase 3 activation as seen in Methotrexate 
induced apopotosis [41] but also in eleosteric acid 
induced apopotosis thru AIF release that was independent 
of Parp activity as well as being Bax and cytochrome 
c independent apoptosis [42].  It is possible that other 
caspases may be involved such as caspase 9 as in case of 
B cell Ag receptor induced apoptosis thru processing of 
caspase 7 and subsequent Parp cleavage [43].  Typically, 
if there are signs of apoptosis, there is appearance of the 
Parp cleavage products 89Kda and 24 Kda fragments 
[39]. Interestingly, in the case of the HN30, no 24 Kda 
fragment was detected only the 89-90 Kda fragment.  In 
the cases of Fadu and WI38 ( Fig. 7 and 9) where there is 
no sign of Parp cleavage neither in the controls nor in the 
treated cells, there has been indication cited of apoptosis 
independent of Parp cleavage thus Parp activity [42].
The down-regulation of nucleolin has been associated 
with initiation of apoptosis in various experimental 
settings such as its down-regulation in C2C12 cells [44], 
siRNA knockdown in Hela cells [45], and use of all-trans 
retinoic acid treatment for induction of apopotsis [46].   
Changing levels of nucleolin have also been associated 
Figure 6:  FAcs analysis of asynchronous WI38 cells 3 days 
post-transfection. NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP 
and pcDNA 3.0 NSP 5a3a.
Figure 7: Western blot analysis of total lysates from 
asynchronous Fadu cells 3 days post-transfection. NT: non-
treated, OB: only buffer, EGFP: only pcDNA3.1/CT-GFP vector, NSP 
5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.Oncotarget 2010; 1:  423 - 435 429 www.impactjournals.com/oncotarget
with corresponding changes in Parp levels as well with 
the possibility that nucleolin may be involved in the 
processing of Parp and subsequent appearance of the 89-
90 Kda Parp fragment associated with apoptosis [47].
Interestingly, we saw a down-regulation in a 
possible high molecular weight p73 isoform in the treated 
HN30 cells (Fig. 8).  It’s been documented that a variety 
of p73 isoforms exist some being (TA) transactivating 
forms which can induce apoptosis through activation of 
p53 target genes while other isoforms being N-terminally 
truncated are anti-apoptotic [48].  It’s possible that the 
high molecular weight isoform found in our study may 
be  post-translational  modification  of  a  p73  isoform 
since various forms of p73 have been identified around 
75, 90 and 140 kDA as found in adult human cortex and 
hippocampus [49].  It is known that p73 demonstrates 
p53 like behavior through transcriptional activation of 
specific genes involved in cell cycle control (e.g. MDM2, 
Gadd45, PCNA, 14-3-3, p21) and in apoptosis and redox 
reactions (e.g. PUMA, NOXA, Bax, PIG2-3, PIG 6-8) 
[50-51].  Though, in p73 induced cell growth arrest and 
apoptosis, there is up-regulation of some but not all genes 
regulated by p53 [52]. There is also evidence that the 
different p73 isoforms possess a quantitative difference 
in transcriptional activity in the induction of p53 target 
genes such as p21, Gadd45, MDM2, and p53 [52] thus 
even leaving the possibility that p73 induces particular 
genes not regulated by p53 [52].
Normally, TAp73 isoforms (alpha, beta, gamma, 
delta) are associated with cell cycle arrest and apoptosis 
though inducing these cellular processes differently 
depending on the cell type and also activating p53 target 
genes differently as well [53].  The apoptosis is evidenced 
by an up-regulation of the particular Tap73 isoform as 
seen with TAp73 alpha and Tap73 beta [53].  While, 
on the other hand, the N-terminally p73 isoforms such 
as delta Np73, ex2p73, and ex2/3p73, which have been 
found to be highly expressed in many cancers, possess 
anti-apoptotic activities [54].  Interesting though, there 
is also evidence that the deltaNp73 isoform can exhibit 
apoptotic activity when overexpressed [55] as also other 
deltaNp73  isoforms  while  targeting  p53  specific  genes 
[55].  Given the specificity of the antibody used for p73 
in our study we cannot be sure about which p73 isoform 
is being detected though the antibody was cited to be able 
to detect all p73 isoforms if present meaning even in the 
70 Kda and 55 Kda range corresponding to the TAp73 
isoforms (α,β,γ,δ,ε,η,ζ) [54, 56] though we were not able 
to detect any bands at that height.
Since the antibody in question recognizes the first 
80 amino acids of p73, it should be able to detect not 
only the apoptotic TAp73 isoforms (α,β,γ,δ,ε,η,ζ) [54] if 
present but also the ex2p73 (α,β,γ, δ,ε,η,ζ) and ex2/3p73 
(α,β,γ, δ,ε,η,ζ) isoforms, which are known to be anti-
apoptotic [54].  The fact there is an evident decrease of a 
high molecular weight isoform in both the HN30 treated 
and the WI38 treated cells, leads us to believe that it may 
represent post-translational modification of either a TAp73 
isoform though one would expect it to be up-regulated 
in case of apoptosis or that of an anti-apoptotic isoform 
relating to the ex2p73 or ex2/3p73 isoforms, since one 
could rationalize a down-regulation of an anti-apoptotic 
isoform during the occurance of apoptosis though we 
cannot exclude the possibility of some unknown role of 
a TAp73 isoform being instead down-regulated in these 
experimental conditions of apoptosis.
In contrast to HN30 and WI38 treated cells (Fig. 8 
and 9), we notice that the Fadu cell line (Fig. 7) instead 
show an up-regulation of p73 which was still identified 
in the same height as those for the HN30 and WI38.  If 
Figure 8: Western blot analysis of total lysates from 
asynchronous Hn30 cells 3 days post-transfection. NT: non-
treated, OB: only buffer, EGFP: only pcDNA3.1/CT-GFP vector, NSP 
5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.
Figure 9: Western blot analysis of total lysates from 
asynchronous WI38 cells 3 days post-transfection. NT: non-
treated, OB: only buffer, EGFP: only pcDNA3.1/CT-GFP vector, NSP 
5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.Oncotarget 2010; 1:  423 - 435 430 www.impactjournals.com/oncotarget
we rationalize that the same or similar isoform is being 
detected in all three cell lines, one could expect this isoform 
to be an anti-apoptotic form post-translationally modified, 
since in the Fadu where there was a slight decrease in 
apoptosis compared to the controls (Fig. 4), we see the 
isoform being up-regulated while in the HN30 and WI38 
it behaves the opposite supporting what was observed 
(Fig. 5 and 6).  This post-translational modification could 
represent a novel form of modification not yet investigated 
or previously detected in these cell lines in the context of 
apoptosis presented.
We see the presence of uncleaved and cleaved 
MDM2 in all controls for the unstressed HN30 and WI38 
cells (Fig. 8 and 9). Though, even so, the Fadu, which 
seemed to show a natural high degree of apoptosis even 
in the controls were not caspase 3 dependent.  There is a 
decrease in both the un-cleaved and cleaved MDM2 in the 
treated for the HN30 and WI30, which seem to accompany 
the down-regulation of the high molecular weight p73 
isoform.  This is contrasted in the treated Fadu cells (Fig. 
7), which show only the presence of an up-regulated 60Kda 
MDM2 product that is up-regulated along with an increase 
in the high molecular weight p73 isoform.   It is known 
that cleavage of MDM2 occurs in apoptosis by means of 
caspase 3 and even so the 60 Kda fragment usually seen 
in apoptosis can be seen in unstressed conditions though 
most likely not involving an apoptosis specific caspase 
3[57]. The appearance of the 60Kda fragment usually 
under these conditions is associated with no Parp activity 
meaning no Parp cleavage [57].
MDM2 down-regulation has been linked to 
sensitizing cells to DNA damaging agents thus promoting 
apoptosis thru p53 pathway though MDM2 can act 
independently of p53 interacting with E2F family member 
proteins [58-59] that are known also to induce apoptosis 
thru p73 apha and beta isoforms [59].  E2F-1 induced 
apoptosis has been associated with decreased levels of 
MDM2 levels, no change in levels of Bax nor in p53 
though there is evidence of Parp cleavage and caspase 
activation implicated with caspase 3 [58].  It’s known that 
p73 can transactivate MDM2 in its up-regulation though 
there is no indication of it down-regulating MDM2 directly 
being cited and though MDM2 is known to be a negative 
regulator of p53 [59-60] promoting its degradation though 
MDM2 does not degrade p73 [59-61].
Nucleolin has been described as negative regulator 
of MDM2, in which nucleolin over-expression determined 
decreased levels of HMD2 leading to apoptosis thru a p53 
dependent pathway involving up-regulation of p21 as well 
[62].  This scenario though is not what we observe for the 
HN30.
Interestingly, when we analyzed NSP 5a3a with a 
protein motif finder available at http://motif.genome.jp/, 
four distinct protein signatures associated with apoptosis 
were detected.  One for Tumor necrosis Factor alpha at 
amino acid sites: 140-158, 154-172, 133-151, and 277-
295; Second for Bcl-2 apoptosis regulatory family at 
amino acid site: 639-667; Third for Daxx protein at amino 
acid site: 276-330; Fourth for CD97 (Fas) protein at 
amino acid site: 76-94.  TNF-alpha induced apoptosis in 
Fl5.12 B lymphoma cells involved caspase 9 activation 
independent of cytochrome c though involved caspase 3 
activation downstream [63].  Caspase 9 could be activated 
by caspase 8 which also can activate caspase 3 as well 
[63].  Even in endoplasmic reticulum (ER) induced 
apoptosis, there can be caspase 9 activation independent 
of cytochrome c though again involving caspase 3 
[64].  The fact that we see relatively constant levels of 
cytochrome c throughout controls and treated in all three 
cell lines seems to indicate that the apoptosis observed in 
independent of cytochrome c.
Tumor necrosis factor alpha (TNF-α) is a cytokine 
known to be involved in both survival pathway via NF-kB 
or apoptosis through caspase cascade activation [65].
When TNF-α is involved in apoptosis, it binds to 
tumor necrosis factor receptor type I (TNFRI) which 
in turns allows the formation of a TRADD complex 
including FADD and por-caspase 8, this it turn activates 
caspase 8 and allows the initiation of the death signaling 
cascade [64, 66].  Caspase 8 can activate other downstream 
caspases directly as well cleave BID, which in association 
with BAX and BAK, can cause release of mitochondrial 
apoptotic factors and further activate the apoptosome and 
other downstream caspases [63, 66].  
TNF-alpha induced has been associated with p73 
though typically relating to its up-regulation or over-
expression such as thru TAp73 alpha and beta associated 
with Parp cleavage and caspase 3 activity [67-68].  Thus 
far, p73 is known to be three distinct pathways leading to 
apoptosis: one involving over-expression of Tap73alpha 
leading to Scotin transactivation thus ER stress and 
apoptosis [69], second involving transactivation of Puma 
with subsequent translocation of Bax and cytochrome c 
release [69], and third involving a death receptor pathway 
in which Tap73 activates death receptors such as CD95 
thus leading to caspase activation and cleavage of death 
substrates (69).  The Tap73 activation in the death receptor 
pathway has been linked also to up-regulation of Fas, a 
tumor necrosis factor related protein (TNFR) though 
involving caspase 3 activation [70].
Since there is evidence of caspase 9 dependent 
but caspase 3 independent pathways [40] as also the 
implication of caspase 8 activation and cleavage of 
caspase 9 in death receptor pathways independent of 
cytochrome c release [71] there may be a novel apoptotic 
pathway in which NSP 5a3a is involved in its induction.   
It has been demonstrated that TNF alpha can induce 
apoptosis thru caspase 8 activation which leads to Bid 
activation and subsequent cytochrome c release from 
the mitochondria followed by caspase 9 activation then 
caspase 3 activation and parp cleavage [66, 72] but also 
thru caspase 8 activation and direct caspase 3 activation Oncotarget 2010; 1:  423 - 435 431 www.impactjournals.com/oncotarget
with Parp cleavage [73-74] yet there is also evidence of 
TNF alpha induced apoptosis independent of caspase 3 
activation thru Bak [75].
Fas induced apoptosis typically involves activation 
of Fas receptor (TNF-R) a tumor necrosis factor member 
by Fas ligand such as FAsL, member of the tumor necrosis 
factor cytokine family [76].  This receptor activation 
leads to recruitment of adaptor proteins such as FADD, 
Daxx, RIP, FAF-1, and FAP-1 [77].  There is subsequent 
recruitment of procaspase 8 to the receptor complex 
where it undergoes self-activation followed by caspase 
3 activation thru two distinct manners: one pathway 
involves caspase 8 cleavage of BID thus triggering 
cytochrome c release.  Cytochrome c release along with 
procaspase 9 and dATP activates caspase 9 which then 
activates caspase 3; the second pathway involves the 
direct activation of caspase 3 by caspase 8 [77].  Though, 
there is   evidence also that Fas/FADD induced apoptosis 
can also be independent of caspase 3 [78].
Daxx protein is known to be involved in Fas-induced 
apoptosis by linking the Fas signaling pathway to the JNK 
pathway through ASK1 activation [79].  Though the role 
of Daxx being either apoptotic or pro-apoptotic has been 
under on-going study and discussion [79], it has been 
found to interact with p73 and function as a transcriptional 
repressor of p53 and its members including p73 [79].
Even though, further investigation of other caspases 
as well as other apoptotic proteins should be investigated 
in NSP 5a3a’s induction of apoptosis in head and neck 
carcinomas as also other cancer cell lines of different 
origins we can rationalize a possible mechanism.  We 
propose the following hypothetical scenario for the 
observed apoptosis in the HN30, WI38, and Fadu cell 
lines. Given the existence of potential protein motifs 
for TNF-a, CD97, BCL-2, and Daxx in NSP 5a3a, there 
is possibility that NSP 5a3a may be involved in death 
receptor mediated apoptosis in a novel manner unseen 
before in structural proteins with spectrin like repeats 
and even in SMC proteins which they have both varying 
degree of homology too.  NSP 5a3a may be able to induce 
apoptosis by possibly activating either the TNF-a or 
Fas induced apoptotic pathway where in the case of Fas 
induced apoptosis, it could interact with Daxx influencing 
thus the regulation of p73 [74], where we could be seeing 
the down-regulation of an anti-apoptotic isoform both in 
the HN30 and WI38.  NSP 5a3a may be affecting levels 
of nucleolin in the case of HN30 by possibly affecting 
one of its transcriptional regulators such as myc [80-81] 
or post-transcriptional regulators such as hnRNP-L [4].   
This in turn would influence the activity and levels of 
Parp in parallel with nucleolin.  The MDM2 levels may 
be possibly modulated by either a novel dependent or 
independent manner involving p73 down-regulation.
What we observe may be a completely novel 
mechanism of apoptosis involving NSP 5a3a, a novel 
structural protein, acting through a novel p73 dependent 
manner independent of p53 and independent of caspase 
3 activation though possibly acting through other 
upstream and downstream caspases such caspase 8, 9 
and 6, 7 respectively, though seemingly independent of 
cytochrome c since there was no observed increase in its 
levels.  Even though NSP 5a3a has been cited to have slight 
to moderate degree of homology to structural maintenance 
proteins [1], SMC overexpression as with SMC 3 has been 
associated with transformation and tumorigenesis [82-83] 
while its down-regulation was associated with apoptosis 
[84] which is not the case with NSP 5a3a.
Naturally, there must be other apoptotic, anti-
apoptotic, and cell cycle proteins involved not yet 
identified that can explain the difference in how and which 
molecular nodes are being activated which are seemingly 
cell-line  specific.    We  demonstrated  that  NSP  5a3a  is 
involved in the induction of apoptosis by an unknown 
p73  dependent  pathway  perhaps  not  yet  indentified 
involving a structural protein such as NSP 5a3a.  Thus, 
we propose that over-expression of NSP 5a3a could be 
a feasible means of therapy by induction of apoptosis if 
used perhaps in a site-directed manner which yet remains 
to be investigated and determined. Though, we should not 
exclude testing its applicability and expression not only in 
other head and neck carcinomas but other cancer cell lines 
of different origins as well as other normal and primary 
cell lines too.  A broader range of cell line testing and 
comparison will ultimately give us a better understanding 
on how NSP 5a3a is inducing apoptosis if so and if there is 
similarity between cancer cell lines and normal cell lines 
and what these implications are for a plausible treatment 
but also its involvement in tumor development and normal 
biological processes.
MAterIAls And MetHods
cell lines and tissue culture
We used following cell lines in this study: Fadu 
(Head and Neck carcinoma), HN30 (Head and Neck 
carcinoma),  and  WI38  (Normal  Lung  fibroblast).   All 
these cell lines were obtained from ATCC and cultured at 
conditions recommended by ATCC except for the HN30 
cell line which was a kind gift from Dr. George Yoo of the 
Department of Otolaryngology, Head and Neck Surgery, 
Wayne State University and Karmanos Cancer Institute, 
Detroit, Michigan. 
dnA transfection and Western blot Analysis
Asynchronous Fadu, HN30, and WI38 cells were 
seeded in 6 well-plates and transfected and optimized 
with Fugene HD (Roche) according to the manufacturer’s 
protocol using 2 ug of plasmid DNA per well.  Plasmids Oncotarget 2010; 1:  423 - 435 432 www.impactjournals.com/oncotarget
used for transfection were the following: pcDNA3.1/CT-
GFP (invitrogen) and pcDNA 3.0 NSP 5a3a.  The NSP 
5a3a cDNA had been cloned from a previous work [1].   
The pcDNA3.1/CT-GFP vector was used to monitor 
transfection efficiency for all cell lines in the study.
 Fadu, HN30, and WI38 cells at three days post-
transfection were harvested mechanically with a scraper, 
spun and washed twice with PBS 1x after which cells were 
prepped for western blot analysis.  Cell pellets were lysed 
using a total lysis buffer (50mM Tris-Cl pH 7.4, 5mM 
EDTA, 250 mM NaCl, 50 mM NaF, .1% Triton X-100, .1 
mM Na3VO4, final volume with dH2O) for 15 minutes on 
ice then for 30 minutes on a rotator at 4 degrees.  Lysates 
were spun down at 13,000 rpm for 15 minutes at 4 degrees 
after which supernatants were collected and protein 
concentration was determined by Bradford Assay.  A total 
of 30 ug of total protein was loaded for each sample and 
separated on 7% SDS-PAGE or 15% gel depending on 
the molecular weight of the proteins to be separated then 
followed by transfer onto Whatman Protran Nitrocellulose 
Transfer Membrane for 1.5 hours at 70 volts at 4 degrees.   
Membranes were pre-blocked overnight at 4 degrees 
in 5% milk buffer TTBS.  Next day, membranes were cut 
and incubated with primary rabbit polyclonal NSP5a3a 
(Novus) at 1/500, primary mouse monoclonal B23 
(Sigma) at 1/500, primary mouse monoclonal MDM2 
(SMP14 Santa Cruz) 1/250, primary rabbit polyclonal p73 
( H-79 Santa Cruz) at 1/250,  primary mouse monoclonal 
p53 clone Pab1801 (Santa Cruz) at 1/100,  primary mouse 
monoclonal alpha-tubulin (Invitrogen) at 1/5000, primary 
mouse mononclonal Bax (2D2 Santa Cruz) at 1/200, 
primary mouse monoclonal caspase-3 (Cell Signaling) at 
1/250, primary mouse monoclonal Cytochrome c (Santa 
Cruz), primary rabbit polyclonal Parp (Cell Signaling) 
1/250 or primary mouse monoclonal Nucleolin (Santa 
Cruz) at 1//200, primary rabbit polyclonal p21 (BD 
Biosciences) at 1/500, and primary mouse monoclonal 
p14 Arf (clone 4c6/4 Santa Cruz) at 1/100 in 5% milk 
buffer TTBS for 2 hours at RT.  
Membranes were then washed 4 times at 15 minute 
intervals in .1%Tween in PBS 1x then were incubated 
with either secondary anti-rabbit HRP (Amersham 
Biosciences) at 1/5000 or secondary anti-mouse HRP 
(Amersham Biosciences) at 1/5000 in 5% milk buffer for 
1 hour at RT.  Membranes were then again washed 4 times 
at 15 minute intervals each and then exposed for 3 minutes 
to ECL Chemiluminescent Detection Reagent (Perkin 
Elmer) to be developed on Kodak x-ray film. 
FAcs Analysis 
Asynchronous Fadu, HN30, and WI38 cells, three 
days post-transfection were trypsinized, spun for 5 
minutes at 1200 rpm and washed in PBS 1x, then fixed 
in 70% ethanol with 1% FBS overnight at 4°C. Next day 
cells were spun for 5 minutes at 1200 rpm and washed in 
PBS 1x twice, afterwards cells were incubated with 300 
ul of PBS1x with PI (propidium iodide) and Rnase for 30 
minutes at 37°C covered and taken to FACS analysis at 
Wistar Institute, Philadelphia, Pa.
light Microscopy
Asynchronous Fadu, HN30, and WI38 cells, three 
days post-transfection were observed for morphological 
changes using Zeiss Axiovert 25 microscope with 10x 
PH1 Zeiis objective.
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